The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
 
Atsushi Nakamura
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Nihonkayaku; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Shionogi (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca; Lilly Japan
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Tatsuro Fukuhara
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Akihiko Gemma
Speakers' Bureau - AstraZeneca
 
Kazuhisa Takahashi
Speakers' Bureau - AstraZeneca Japan; Lilly Japan
Research Funding - AstraZeneca Japan (Inst); Lilly Japan (Inst)
 
Yuka Fujita
Honoraria - ARKRAY; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Pfizer; Taiho Pharmaceutical
 
Toshiyuki Harada
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Hisamitsu Pharmaceutical; Taiho Pharmaceutical
 
Koichi Minato
Research Funding - Bristol-Myers Squibb (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Kei Takamura
No Relationships to Disclose
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Toshihiro Nukiwa
Consulting or Advisory Role - Asahi Kasei; Boehringer Ingelheim